Lilly Q1 revenue climbs 55% to $19.8 billion as orforglipron launches
The company reported 20,000 prescriptions for its oral GLP-1 in the first 20 days, with 80% of those patients new to the class.
TR
By Tom Reyes · Markets Editor
May 4 03:00 ETSource: 24/7 Wall St.
The wire
- 01Eli Lilly posted Q1 2026 revenue of $19.80 billion, up 55.5%, with non-GAAP EPS of $8.55 and full-year guidance raised to $82.0-$85.0 billion.
- 02Volume rose 65% while realized prices fell 13% on rebates and access deals, a signal for anyone tracking incretin pricing and payer coverage.
- 03Management says oral orforglipron, marketed as Foundayo, is drawing GLP-1-naive patients; durability of that uptake and the retatrutide filing timeline remain unsettled.
From the source
Read at 247wallst.comEli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%
The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be replaced with the “Mounjaro economy” now that Eli Lilly is controlling 60% of the GLP-1 market . Lilly’s Q1 2026 earnings report backs that up.